Parkinson's Disease

Top three unmet needs to target in Parkinson’s disease
Top three unmet needs to target in Parkinson’s disease
Clinical Trials Arena
Parkinson's Disease
drug devlopment
Flag link:
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
Stat
Parkinson's Disease
Michael J Fox
Flag link:
FTC says patent battle over Parkinson's drug could have 'significant implications' for patients
FTC says patent battle over Parkinson's drug could have 'significant implications' for patients
Endpoints
FTC
Parkinson's Disease
Apokyn
Supernus Pharmaceuticals
Sage Chemical
patents
Flag link:
Cerevel blames Covid for delayed neuroscience studies, says president is leaving
Cerevel blames Covid for delayed neuroscience studies, says president is leaving
Endpoints
Cerevel Therapeutics
COVID-19
epilepsy
Parkinson's Disease
darigabat
CVL-871
Flag link:
Working its way through a CRL on lead drug, Supernus taps $150M loan
Working its way through a CRL on lead drug, Supernus taps $150M loan
Endpoints
Supernus Pharmaceuticals
FDA
Parkinson's Disease
SPN-830
Flag link:
Inhibikase, FDA find common ground to lift hold on Parkinson's drug
Inhibikase, FDA find common ground to lift hold on Parkinson's drug
Fierce Biotech
Inhibikase Therapeutics
Parkinson's Disease
IkT-148009
clinical trials
Flag link:
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Fierce Biotech
Ipsen
IRLAB
clinical trials
Parkinson's Disease
mesdopetam
Flag link:
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
Fierce Biotech
Voyager Therapeutics
Neurocrine
capsids
CNS
Parkinson's Disease
Flag link:
CuraSen reports positive data from Parkinson’s disease oral therapy trial
CuraSen reports positive data from Parkinson’s disease oral therapy trial
Clinical Trials Arena
CuraSen
clinical trials
CST-103
Parkinson's Disease
Flag link:
FDA accepts Amneal’s NDA for IPX203 to treat Parkinson’s disease
FDA accepts Amneal’s NDA for IPX203 to treat Parkinson’s disease
Pharmaceutical Business Review
Amneal
FDA
IPX203
Parkinson's Disease
Flag link:
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS
BioSpace
NRG Therapeutics
funding
Parkinson's Disease
ALS
Flag link:
Inhibikase stock sinks on FDA's unexpected clinical hold for lead asset's Parkinson's trial
Inhibikase stock sinks on FDA's unexpected clinical hold for lead asset's Parkinson's trial
Fierce Biotech
Inhibikase Therapeutics
Parkinson's Disease
IkT-148009
Flag link:
FDA spurns Supernus for Parkinson's drug, noting application issues 'across several areas'
FDA spurns Supernus for Parkinson's drug, noting application issues 'across several areas'
Endpoints
Supernus Pharmaceuticals
FDA
Parkinson's Disease
SPN-830
Flag link:
Biogen, Denali begin late-stage testing of Parkinson’s drug
Biogen, Denali begin late-stage testing of Parkinson’s drug
BioPharma Dive
Biogen
Denali Therapeutics
Parkinson's Disease
clinical trials
BIIB122
Flag link:
Qiagen to Develop Companion Dx for New Parkinson's Drug
Qiagen to Develop Companion Dx for New Parkinson's Drug
Medical Devices and Diagnostics Industry
Qiagen
companion diagnostics
Parkinson's Disease
Medtech
Neuron23
Flag link:
Amneal asks FDA to approve another new formulation of Parkinson’s combo drug 
Amneal asks FDA to approve another new formulation of Parkinson’s combo drug 
Endpoints
Amneal
Parkinson's Disease
carbidopa/levodopa
IPX203
Flag link:
Amneal submits NDA to US FDA for Parkinson’s disease treatment
Amneal submits NDA to US FDA for Parkinson’s disease treatment
Pharmaceutical Business Review
Amneal
FDA
Parkinson's Disease
IPX203
Flag link:
Annovis Bio doses first subject in Phase III Parkinson’s trial
Annovis Bio doses first subject in Phase III Parkinson’s trial
Clinical Trials Arena
Annovis Bio
clinical trials
buntanetap
Parkinson's Disease
Flag link:
Inhibikase doses first subject in Phase IIa Parkinson’s treatment trial
Inhibikase doses first subject in Phase IIa Parkinson’s treatment trial
Clinical Trials Arena
Inhibikase Therapeutics
clinical trials
Parkinson's Disease
IkT-148009
Flag link:
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Pharmaforum
Kyowa Kirin
KW-6356
clinical trials
Parkinson's Disease
Flag link:

Pages